Progress of research on proteomics of diabetic nephropathy

doi:10.3877/cma.j.issn.2095-3216.2018.04.010

Abstract

Abstract:

Diabetic nephropathy (DN) is the most common microvascular complication of diabetes, and also an important cause for end-stage renal disease (ESRD). Microalbuminuria is not a reliable indicator for predicting the progression of DN. Looking for early biomarkers and investigating the mechanisms of renal early lesions in DN are currently the paramount missions. Proteomics technologies have developed rapidly in recent years, and proteomics research on urine, blood and kidney tissue of DN patients may provide new hope for early diagnosis and treatment of DN. This review summarized the major technologies of proteomics and its recent progress in DN.

Key words: Diabetes mellitus, Diabetic nephropathy, Proteomics

Yang Liu, Qingli Cheng, Guang Yang. Progress of research on proteomics of diabetic nephropathy[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2018, 07(04): 182-185.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2018.04.010

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2018/V07/I04/182

References 35

[1]	Currie G, Delles C. Urinary proteomics for diagnosis and monitoring of diabetic nephropathy [J]. Curr Diab Rep, 2016, 16(11): 104.
[2]	Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China [J]. N Engl J Med, 2010, 362(12): 1090-1101.
[3]	Lin CH, Chang YC, Chuang LM. Early detection of diabetic kidney disease: present limitations and future perspectives [J]. World J Diabetes, 2016, 7(14): 290-301.
[4]	Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes [J]. N Engl J Med, 2003, 348(23): 2285-2293.
[5]	Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes [J]. Diabetes, 2005, 54(10): 2983-2987.
[6]	Son MK, Yoo HY, Kwak BO, et al. Regression and progression of microalbuminuria in adolescents with childhood onset diabetes mellitus [J]. Ann Pediatr Endocrinol Metab, 2015, 20(1): 13-20.
[7]	Wasinger VC, Cordwell SJ, Cerpa－Poljak A, et al. Progress with gene－product mapping of the Mollicutes: Mycoplasma genitalium [J]. Electrophoresis, 1995, 16(7): 1090-1094.
[8]	Breker M, Schuldiner M. The emergence of proteome－wide technologies: systematic analysis of proteins comes of age [J]. Nat Rev Mol Cell Biol, 2014, 15(7): 453-464.
[9]	Bantscheff M, Lemeer S, Savitski MM, et al. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present [J]. Anal Bioanal Chem, 2012, 404(4): 939-965.
[10]	Meier M, Kaiser T, Herrmann A, et al. Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis [J]. J Diabetes Complications, 2005, 19(4): 223-232.
[11]	Otu HH, Can H, Spentzos D, et al. Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy [J]. Diabetes Care, 2007, 30(3): 638-643.
[12]	Jin J, Ku YH, Kim Y, et al. Differential proteome profiling using iTRAQ in microalbuminuric and normoalbuminuric type 2 diabetic patients [J]. Exp Diabetes Res, 2012, 2012: 168602.
[13]	Thrailkill KM, Nimmo T, Bunn RC, et al. Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin [J]. Diabetes Care, 2009, 32(7): 1266-1268.
[14]	Hryciw DH, Lee EM, Pollock CA, et al. Molecular changes in proximal tubule function in diabetes mellitus [J]. Clin Exp Pharmacol Physiol, 2004, 31(5－6): 372-379.
[15]	Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors [J]. Nat Rev Mol Cell Biol, 2002, 3(4): 256-266.
[16]	Jiang H, Guan G, Zhang R, et al. Identification of urinary soluble E－cadherin as a novel biomarker for diabetic nephropathy [J]. Diabetes Metab Res Rev, 2009, 25(3): 232-241.
[17]	Merchant ML, Perkins BA, Boratyn GM, et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria [J]. J Am Soc Nephrol, 2009, 20(9): 2065-2074.
[18]	Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease [J]. Mol Cell Proteomics, 2010, 9(11): 2424-2437.
[19]	Schanstra JP, Zurbig P, Alkhalaf A, et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides [J]. J Am Soc Nephrol, 2015, 26(8): 1999-2010.
[20]	Argiles A, Siwy J, Duranton F, et al. CKD273, a new proteomics classifier assessing CKD and its prognosis [J]. PLoS One, 2013, 8(5): e62837.
[21]	Andersen S, Mischak H, Zurbig P, et al. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria [J]. BMC Nephrol, 2010, 11: 29.
[22]	Lindhardt M, Persson F, Currie G, et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial [J]. BMJ Open, 2016, 6(3): e010310.
[23]	Betz BB, Jenks SJ, Cronshaw AD, et al. Urinary peptidomics in a rodent model of diabetic nephropathy highlights epidermal growth factor as a biomarker for renal deterioration in patients with type 2 diabetes [J]. Kidney Int, 2016, 89(5): 1125-1135.
[24]	Siwy J, Zoja C, Klein J, et al. Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles [J]. PLoS One, 2012, 7(12): e51334.
[25]	Zubiri I, Posada－Ayala M, Benito－Martin A, et al. Kidney tissue proteomics reveals regucalcin downregulation in response to diabetic nephropathy with reflection in urinary exosomes [J]. Transl Res, 2015, 166(5): 474-484.
[26]	Zubiri I, Posada－Ayala M, Sanz－Maroto A, et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label－free comparative analysis [J]. J Proteomics, 2014, 96: 92-102.
[27]	Raimondo F, Corbetta S, Morosi L, et al. Urinary exosomes and diabetic nephropathy: a proteomic approach [J]. Mol Biosyst, 2013, 9(6): 1139-1146.
[28]	Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects [J]. Mol Cell Proteomics, 2002, 1(11): 845-867.
[29]	Kim HJ, Cho EH, Yoo JH, et al. Proteome analysis of serum from type 2 diabetics with nephropathy [J]. J Proteome Res, 2007, 6(2): 735-743.
[30]	Cho EH, Kim MR, Kim HJ, et al. The discovery of biomarkers for type 2 diabetic nephropathy by serum proteome analysis [J]. Proteomics Clin Appl, 2007, 1(4): 352-361.
[31]	Yang Y, Zhang S, Lu B, et al. Predicting diabetic nephropathy by serum proteomic profiling in patients with type 2 diabetes [J]. Wien Klin Wochenschr, 2015, 127(17－18): 669-674.
[32]	Nakatani S, Kakehashi A, Ishimura E, et al. Targeted proteomics of isolated glomeruli from the kidneys of diabetic rats: sorbin and SH3 domain containing 2 is a novel protein associated with diabetic nephropathy [J]. Exp Diabetes Res, 2011, 2011: 979354.
[33]	Zhang D, Yang H, Kong X, et al. Proteomics analysis reveals diabetic kidney as a ketogenic organ in type 2 diabetes [J]. Am J Physiol Endocrinol Metab, 2011, 300(2): E287-E295.
[34]	Fugmann T, Borgia B, Revesz C, et al. Proteomic identification of vanin－1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy [J]. Kidney Int, 2011, 80(3): 272-281.
[35]	Tsai PY, Chen SM, Chen HY, et al. Proteome analysis of altered proteins in streptozotocin－induced diabetic rat kidney using the fluorogenic derivatization－liquid chromatography－tandem mass spectrometry method [J]. Biomed Chromatogr, 2013, 27(3): 382-389.

Please choose a citation manager

Content to export